<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266797</url>
  </required_header>
  <id_info>
    <org_study_id>S13-00108</org_study_id>
    <nct_id>NCT02266797</nct_id>
  </id_info>
  <brief_title>Effect of Intravenous Corticosteroid Injections on Dysphagia After Cervical Spine Surgery</brief_title>
  <official_title>Effect of Intravenous Corticosteroid Injections on Dysphagia After Anterior Cervical Spine Surgery: a Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study to examine the effect of local
      intravenous steroids following anterior cervical spine surgery on the development of
      dysphagia in patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this randomized, double-blind, placebo-controlled study is to examine the
      effect of local intravenous steroids following anterior cervical spine surgery on the
      development of dysphagia in patients. This study aims to investigate if there is a difference
      in the efficacy of intravenous steroids compared to a placebo of physiological saline for
      patients undergoing anterior cervical spine surgery. Furthermore, this study aims to
      investigate the correlation between radiographic measurements of soft tissue swelling and the
      severity of dysphagia for patients. Finally, this study aims to examine the impact of
      intravenous steroids on nausea and radicular pain in patients. Secondary outcome measures
      will include patient focused outcomes questionnaires, pain medication requirements, and
      fusion rates.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intravenous Corticosteroids Effect on Post-operative Dysphagia</measure>
    <time_frame>12 months</time_frame>
    <description>The severity of dysphagia will be evaluated by dysphagia questionnaires and a two week postoperative swallow evaluation by a licensed swallowing expert. If recommended by the swallow evaluation, a videofluoroscopic swallow study (VFSS) will be performed to further evaluate the severity of dysphagia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Correlation Between Radiographic Data and the Extent of Dysphagia in Patients.</measure>
    <time_frame>12 months</time_frame>
    <description>Soft-tissue swelling will be measured by the anterior cervical soft-tissue shadow width on lateral cervical radiographs. The extent of dysphagia will be evaluated by the dysphagia questionnaires, the swallow evaluation, and the VFSS, if necessary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Efficacy of Intravenous Steroids on Aspiration Rates of Patients Undergoing Anterior Cervical Spine Surgery.</measure>
    <time_frame>12 months</time_frame>
    <description>Aspiration rates will be evaluated by the percentage of patients in each group with post-operative aspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine the Impact of Dexamethasone on the Development of Postoperative Nausea.</measure>
    <time_frame>Immediate post-operatively</time_frame>
    <description>This will be quantified by the visual analogue scale (VAS) questionnaire for nausea and measuring the number of vomiting episodes following surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine the Impact of Dexamethasone on Radicular Pain.</measure>
    <time_frame>12 months</time_frame>
    <description>This will be quantified by the NDI questionnaire and VAS questionnaire for neck pain and arm pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Examine Whether Intravenous Steroids Affect the Outcomes of Surgery, for Example, Fusion Rates.</measure>
    <time_frame>12 months</time_frame>
    <description>The outcomes of surgery will be examined through the 1 year post-operative appointment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Dysphagia After Anterior Cervical Decompression and Fusion of the Spine</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will receive doses of intravenous physiological saline solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.</description>
    <arm_group_label>Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects included in the study are patients undergoing an anterior cervical spine
             procedure.

        Exclusion Criteria:

          -  Patients with greater than ASA grade II will be excluded. Patients with
             non-degenerative conditions, such as trauma, tumors, infection, radiation, and
             diabetes will be excluded. Patients with posterior procedures will be excluded.
             Patients with clinical pre-operative dysphagia, indicated by a score of 3 or higher on
             the EAT-10 questionnaire,19 will also be excluded. Patients who are pregnant will be
             excluded from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center for Musculoskeletal Care (CMC)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Spine Institute</name>
      <address>
        <city>Westbury</city>
        <state>New York</state>
        <zip>11590</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Leonard R, Belafsky P. Dysphagia following cervical spine surgery with anterior instrumentation: evidence from fluoroscopic swallow studies. Spine (Phila Pa 1976). 2011 Dec 1;36(25):2217-23. doi: 10.1097/BRS.0b013e318205a1a7.</citation>
    <PMID>21325988</PMID>
  </reference>
  <reference>
    <citation>Bazaz R, Lee MJ, Yoo JU. Incidence of dysphagia after anterior cervical spine surgery: a prospective study. Spine (Phila Pa 1976). 2002 Nov 15;27(22):2453-8.</citation>
    <PMID>12435974</PMID>
  </reference>
  <reference>
    <citation>Stewart M, Johnston RA, Stewart I, Wilson JA. Swallowing performance following anterior cervical spine surgery. Br J Neurosurg. 1995;9(5):605-9.</citation>
    <PMID>8561932</PMID>
  </reference>
  <reference>
    <citation>Winslow CP, Winslow TJ, Wax MK. Dysphonia and dysphagia following the anterior approach to the cervical spine. Arch Otolaryngol Head Neck Surg. 2001 Jan;127(1):51-5.</citation>
    <PMID>11177014</PMID>
  </reference>
  <reference>
    <citation>Martin RE, Neary MA, Diamant NE. Dysphagia following anterior cervical spine surgery. Dysphagia. 1997 Winter;12(1):2-8; discussion 9-10.</citation>
    <PMID>8997826</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2014</study_first_submitted>
  <study_first_submitted_qc>October 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <results_first_submitted>October 30, 2015</results_first_submitted>
  <results_first_submitted_qc>February 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2016</results_first_posted>
  <last_update_submitted>February 16, 2016</last_update_submitted>
  <last_update_submitted_qc>February 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deglutition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone</title>
          <description>Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
Dexamethasone: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>Subject will receive doses of intravenous physiological saline solution.
Saline: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone</title>
          <description>Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
Dexamethasone: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>Subject will receive doses of intravenous physiological saline solution.
Saline: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intravenous Corticosteroids Effect on Post-operative Dysphagia</title>
        <description>The severity of dysphagia will be evaluated by dysphagia questionnaires and a two week postoperative swallow evaluation by a licensed swallowing expert. If recommended by the swallow evaluation, a videofluoroscopic swallow study (VFSS) will be performed to further evaluate the severity of dysphagia.</description>
        <time_frame>12 months</time_frame>
        <population>Data not available due to premature halting of study</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
Dexamethasone: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subject will receive doses of intravenous physiological saline solution.
Saline: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Intravenous Corticosteroids Effect on Post-operative Dysphagia</title>
          <description>The severity of dysphagia will be evaluated by dysphagia questionnaires and a two week postoperative swallow evaluation by a licensed swallowing expert. If recommended by the swallow evaluation, a videofluoroscopic swallow study (VFSS) will be performed to further evaluate the severity of dysphagia.</description>
          <population>Data not available due to premature halting of study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Correlation Between Radiographic Data and the Extent of Dysphagia in Patients.</title>
        <description>Soft-tissue swelling will be measured by the anterior cervical soft-tissue shadow width on lateral cervical radiographs. The extent of dysphagia will be evaluated by the dysphagia questionnaires, the swallow evaluation, and the VFSS, if necessary.</description>
        <time_frame>12 months</time_frame>
        <population>Data not available due to premature halting of study</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
Dexamethasone: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subject will receive doses of intravenous physiological saline solution.
Saline: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Correlation Between Radiographic Data and the Extent of Dysphagia in Patients.</title>
          <description>Soft-tissue swelling will be measured by the anterior cervical soft-tissue shadow width on lateral cervical radiographs. The extent of dysphagia will be evaluated by the dysphagia questionnaires, the swallow evaluation, and the VFSS, if necessary.</description>
          <population>Data not available due to premature halting of study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Efficacy of Intravenous Steroids on Aspiration Rates of Patients Undergoing Anterior Cervical Spine Surgery.</title>
        <description>Aspiration rates will be evaluated by the percentage of patients in each group with post-operative aspiration.</description>
        <time_frame>12 months</time_frame>
        <population>Data not available due to premature halting of study</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
Dexamethasone: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subject will receive doses of intravenous physiological saline solution.
Saline: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>The Efficacy of Intravenous Steroids on Aspiration Rates of Patients Undergoing Anterior Cervical Spine Surgery.</title>
          <description>Aspiration rates will be evaluated by the percentage of patients in each group with post-operative aspiration.</description>
          <population>Data not available due to premature halting of study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Examine the Impact of Dexamethasone on the Development of Postoperative Nausea.</title>
        <description>This will be quantified by the visual analogue scale (VAS) questionnaire for nausea and measuring the number of vomiting episodes following surgery.</description>
        <time_frame>Immediate post-operatively</time_frame>
        <population>Data not available due to premature halting of study</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
Dexamethasone: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subject will receive doses of intravenous physiological saline solution.
Saline: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Examine the Impact of Dexamethasone on the Development of Postoperative Nausea.</title>
          <description>This will be quantified by the visual analogue scale (VAS) questionnaire for nausea and measuring the number of vomiting episodes following surgery.</description>
          <population>Data not available due to premature halting of study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Examine the Impact of Dexamethasone on Radicular Pain.</title>
        <description>This will be quantified by the NDI questionnaire and VAS questionnaire for neck pain and arm pain.</description>
        <time_frame>12 months</time_frame>
        <population>Data not available due to premature halting of study</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
Dexamethasone: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subject will receive doses of intravenous physiological saline solution.
Saline: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Examine the Impact of Dexamethasone on Radicular Pain.</title>
          <description>This will be quantified by the NDI questionnaire and VAS questionnaire for neck pain and arm pain.</description>
          <population>Data not available due to premature halting of study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Examine Whether Intravenous Steroids Affect the Outcomes of Surgery, for Example, Fusion Rates.</title>
        <description>The outcomes of surgery will be examined through the 1 year post-operative appointment.</description>
        <time_frame>12 months</time_frame>
        <population>Data not available due to premature halting of study</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone</title>
            <description>Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
Dexamethasone: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Subject will receive doses of intravenous physiological saline solution.
Saline: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Examine Whether Intravenous Steroids Affect the Outcomes of Surgery, for Example, Fusion Rates.</title>
          <description>The outcomes of surgery will be examined through the 1 year post-operative appointment.</description>
          <population>Data not available due to premature halting of study</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone</title>
          <description>Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
Dexamethasone: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Subject will receive doses of intravenous physiological saline solution.
Saline: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Gerling</name_or_title>
      <organization>NYU Langone Medical Center</organization>
      <phone>(718) 630-8600</phone>
      <email>Michael.Gerling@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

